Prostate cancer‐specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Edward Christopher Dee; Michelle D Nezolosky; Fallon E Chipidza; Melaku A Arega; Santino S Butler; Sybil T Sha; Brandon A Mahal; Paul L Nguyen; David D Yang; Vinayak Muralidhar

doi:10.1002/pros.24041

Back

Prostate cancer‐specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Journal article

Peer reviewed

Prostate cancer‐specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Edward Christopher Dee, Michelle D Nezolosky, Fallon E Chipidza, Melaku A Arega, Santino S Butler, Sybil T Sha, Brandon A Mahal, Paul L Nguyen, David D Yang and Vinayak Muralidhar

The Prostate, Vol.80(13), pp.1128-1133

2020-09

DOI: https://doi.org/10.1002/pros.24041

PMID: 32659024

Metrics

48 Record Views

12 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.147 Prostate Cancer; 1.147.97 Prostate Cancer
Web Of Science research areas: Endocrinology & Metabolism; Urology & Nephrology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Prostate cancer‐specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities
Creators: Edward Christopher Dee - Dana‐Farber Cancer Institute/Brigham and Women's HospitalHarvard Medical School Boston Massachusetts, Harvard Medical School Boston Massachusetts
Michelle D Nezolosky - Dana‐Farber Cancer Institute/Brigham and Women's HospitalHarvard Medical School Boston Massachusetts
Fallon E Chipidza - Dana‐Farber Cancer Institute/Brigham and Women's HospitalHarvard Medical School Boston Massachusetts
Melaku A Arega - Harvard Medical School Boston Massachusetts
Santino S Butler - Dana‐Farber Cancer Institute/Brigham and Women's HospitalHarvard Medical School Boston Massachusetts, Harvard Medical School Boston Massachusetts
Sybil T Sha - Dana‐Farber Cancer Institute/Brigham and Women's HospitalHarvard Medical School Boston Massachusetts, Geisel School of Medicine at Dartmouth Hanover New Hampshire
Brandon A Mahal - Department of Radiation OncologyUniversity of Miami Miller School of Medicine Miami Florida, Office of Community Outreach and EngagementSylvester Comprehensive Cancer Center Florida
Paul L Nguyen - Dana‐Farber Cancer Institute/Brigham and Women's HospitalHarvard Medical School Boston Massachusetts
David D Yang - Dana‐Farber Cancer Institute/Brigham and Women's HospitalHarvard Medical School Boston Massachusetts
Vinayak Muralidhar - Dana‐Farber Cancer Institute/Brigham and Women's HospitalHarvard Medical School Boston Massachusetts
Publication Details: The Prostate, Vol.80(13), pp.1128-1133
Academic Unit: Miller School of Medicine; UMMG Dept of Radiation Oncology
Language: English
Resource Type: Journal article
PMID: 32659024
Record Identifier: 991031597763002976